Merck & Co Inc

-0.46 (-0.53%)
4:24:20 PM EDT: $86.30 +0.12 (+0.14%)
Products, Regulatory

Merck To Initiate New Phase 3 Study With Lower Dose Of Islatravir In Combination With Doravirine For Treating HIV

Published: 09/20/2022 11:31 GMT
Merck & Co Inc (MRK) - Merck to Initiate New Phase 3 Clinical Program With Lower Dose of Daily Oral Islatravir in Combination With Doravirine for Treatment of People With Hiv-1 Infection.
Merck & Co Inc - Monthly Oral Islatravir Development for Pre-exposure Prophylaxis (prep) to Be Discontinued.
Merck & Co Inc - Merck Continues to Evaluate Other Long-acting Prep Candidates.
Merck & Co Inc - One Study Will Evaluate Dor/isl in Previously Untreated Adults With Hiv-1 Infection.
Merck & Co Inc - Two Studies Will Evaluate Dor/isl As a Switch in Art in Adults With Hiv-1 Infection Who Are Virologically Suppressed.
Merck & Co Inc - Participants in Ongoing Phase 3 Prep Once-monthly Oral Studies Will Continue to Be Monitored.
Merck & Co Inc - a Phase 1b Study in Adults With Hiv-1 Infection Assessing Mk-8527, a Novel Nrtti Candidate, Will Commence Shortly.